Home | Welcome to Contract Pharma   
Last Updated Tuesday, September 23 2014
Print

Cook General Bio To Make HemaXellerate I



By Gil Roth



Published November 1, 2013
Related Searches: Preclinical Clinical Trial Biopharma CMO
Bio-Matrix Scientific Group's Regen BioPharma subsidiary will use Cook General Biotechnology as its CMO to make clinical supplies of HemaXellerate I. HemaXellerate I is a personalized stem cell treatment that utilizes fat derived cells to inhibit the biological processes responsible for aplastic anemia. The initial batches will be utilized for completing preclinical experiments requested by the FDA for a clinical trial using HemaXellerate I as a therapeutic for treatment resistant aplastic anemia.

"We are excited to work with the team at Regen BioPharma in producing clinical grade HemaXellerate I, initially for preclinical studies, and subsequently for the clinical trial itself," said Erik J. Woods, Ph.D., chief executive officer of Cook General Biotechnology.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On